| Patent application number | Description | Published |
|---|
| 20090060913 | COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES - The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. | 03-05-2009 |
| 20090098118 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. | 04-16-2009 |
| 20090110688 | COMBINATION THERAPY OF TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. | 04-30-2009 |
| 20090162359 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 06-25-2009 |
| 20090162360 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 06-25-2009 |
| 20090175851 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 07-09-2009 |
| 20090232811 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 09-17-2009 |
| 20090246197 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) - The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. | 10-01-2009 |
| 20100015627 | SELECTION METHOD - The current invention comprises a method for the selection of a mammalian cell by transfecting a mammalian cell with a nucleic acid comprising a part of a nucleic acid encoding a polypeptide that catalyzes an α1,6-glycosidic bond formation between fucose and an asparagine-linked N-acetylglucosamine and cultivating the transfected mammalian cell in the presence of Lens culinaris agglutinin (LCA) and selecting a mammalian cell viable under these conditions. | 01-21-2010 |
| 20100028949 | SHRNA-MEDIATED INHIBITION OF EXPRESSION OF ALPHA 1,6-FUCOSYLTRANSFERASE - The current invention comprises a method for producing a heterologous polypeptide with a reduced degree of fucose modification in a mammalian cell by cultivating the mammalian cell under conditions suitable for the expression of said heterologous polypeptide, and recovering the heterologous polypeptide from the mammalian cell or the culture, wherein in said mammalian cell the enzymatic activity of α1,6-fucosyltransferase is reduced by means of an shRNA directed against α1,6-fucosyltransferase mRNA. | 02-04-2010 |
| 20100081796 | BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIES - The present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies. | 04-01-2010 |
| 20100111967 | BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 05-06-2010 |
| 20100159489 | PROMOTER - The current invention reports a promoter having the nucleic acid sequence of SEQ ID NO: 02, or SEQ ID NO: 03, or SEQ ID NO: 04, or SEQ ID NO: 06, which is a 5′ shortened SV40 promoter with reduced promoter strength especially useful for the limited expression of heterologous polypeptides or selectable markers. | 06-24-2010 |
| 20100159587 | ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 - The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 06-24-2010 |
| 20100310581 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) - The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. | 12-09-2010 |
| 20110086025 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. | 04-14-2011 |
| 20110151513 | SHRNA-MEDIATED INHIBITION OF EXPRESSION OF ALPHA-1,6-FUCOSYLTRANSFERASE - The current invention comprises a method for producing a heterologous polypeptide with a reduced degree of fucose modification in a mammalian cell by cultivating the mammalian cell under conditions suitable for the expression of said heterologous polypeptide, and recovering the heterologous polypeptide from the mammalian cell or the culture, wherein in said mammalian cell the enzymatic activity of α1,6-fucosyltransferase is reduced by means of an shRNA directed against α1,6-fucosyltransferase mRNA. | 06-23-2011 |
